Phio Pharmaceuticals Corp. (NASDAQ:PHIO) traded at $2.85 at last check on Tuesday, Aug 11, making a downturn move of -3.06% on its previous day’s price.

Looking at the stock we see that its previous close was $2.94 and the beta (5Y monthly) reads 2.43 with the day’s price range being $2.8000 – 3.1700. The company has a 12-month trailing PE ratio of 0. In terms of its 52-week price range, PHIO has a high of $21.17 and a low of $1.6. The company’s stock has gained about 22.84% over that past 30 days.

On the other hand, looking at the outlook for the PHIO stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of Hold. Long term indicators on average place the stock in the category of 50% Sell.

Based on estimates by 1 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Phio Pharmaceuticals Corp. (PHIO) stock as a Hold, while 1 rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas none suggests the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the PHIO stock currently stands at 0, and the current price level is 13.82% off its SMA20 and 15.13% from its 50-day simple moving average. The RSI (14) is pointing at 63.87 while the volatility over the past week is 1000% and drops to 8.74% over the past one month. The beta value is 2.43, while the average true range (ATR) is currently pointing at 0.24. The average price target for the stock over the next 12 months is $6.5, with the estimates having a low of $4 and a high of $9. These price ends are 40.35% and +215.79% off the current price level respectively, although investors could be excited at the prospect of a +128.07% if the PHIO share price touches on the median price of $6.5.

Let’s briefly compare Phio (PHIO) stock to its peers. We find that today’s price change of -3.06% and -85.67% over the past 12 months for PHIO competes that of Zoetis Inc Cl A (ZTS), which has seen its stock price fall -0.73% in the latest trading session and is +26.6% over the last one year. Another of its peers Takeda Pharmaceutical Co. Ltd (TAK) has climbed 1.65% today, and is +6.26% up over the past year, while Catalent Inc (CTLT) is also down -3.06% yet its price remains in the red at -85.67% over the same period. Zoetis has a P/E ratio of 46.68 compared to Phio’s 0 and Takeda’s 22.78. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -0.8% and -0.38%, respectively, in early deals.

Coming back to Phio Pharmaceuticals Corp. (NASDAQ:PHIO), we note that the average 3-month trading volume was 1.41 Million, while that of the preceding 10-day period stands at 844.97 Million. Current shares outstanding are 5.78 Million.

According to data from Thomson Reuters, insiders hold 6.76% of the company’s shares while institutions hold 30.47%. The data shows that short shares as of July 14, 2020, stood at 99.47 Million at a short ratio of 0.2. This represents a 1.72% Short interest in Shares outstanding on July 14, 2020. Shares short dropped in July from the previous month at 223.81 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -69.7% down in year-to-date price movement.